HRP20171578T1 - Čvrsta disperzija - Google Patents
Čvrsta disperzija Download PDFInfo
- Publication number
- HRP20171578T1 HRP20171578T1 HRP20171578TT HRP20171578T HRP20171578T1 HR P20171578 T1 HRP20171578 T1 HR P20171578T1 HR P20171578T T HRP20171578T T HR P20171578TT HR P20171578 T HRP20171578 T HR P20171578T HR P20171578 T1 HRP20171578 T1 HR P20171578T1
- Authority
- HR
- Croatia
- Prior art keywords
- solid dispersion
- methyl
- cellulose
- weight
- hydroxypropyl
- Prior art date
Links
- 239000007962 solid dispersion Substances 0.000 title claims 21
- 239000004815 dispersion polymer Substances 0.000 claims 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 8
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 claims 6
- 229920001577 copolymer Polymers 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims 2
- 239000011118 polyvinyl acetate Substances 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 229940068984 polyvinyl alcohol Drugs 0.000 claims 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 2
- 125000005591 trimellitate group Chemical group 0.000 claims 2
- 229920002554 vinyl polymer Polymers 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- UGZICOVULPINFH-UHFFFAOYSA-N acetic acid;butanoic acid Chemical compound CC(O)=O.CCCC(O)=O UGZICOVULPINFH-UHFFFAOYSA-N 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- FYUWIEKAVLOHSE-UHFFFAOYSA-N ethenyl acetate;1-ethenylpyrrolidin-2-one Chemical compound CC(=O)OC=C.C=CN1CCCC1=O FYUWIEKAVLOHSE-UHFFFAOYSA-N 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 229920006163 vinyl copolymer Polymers 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Glass Compositions (AREA)
- Inorganic Insulating Materials (AREA)
- Optical Communication System (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (15)
1. Čvrsta disperzija, naznačena time što sadrži N4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloksi)-3-metilfenil)-N6-(4,4-dimetil-4,5-dihidrooksazol-2-il)kinazolin-4,6-diamin i disperzijski polimer.
2. Čvrsta disperzija u skladu s patentnim zahtjevom 1, naznačena time što sadrži amorfni N4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloksi)-3-metilfenil)-N6-(4,4-dimetil-4,5-dihidrooksazol-2-il)kinazolin-4,6-diamin.
3. Čvrsta disperzija prema patentnim zahtjevima 1 ili 2, naznačena time što se disperzijski polimer bira između vinilnih polimera i kopolimera, PVP-VA, polivinil-alkohola, polivinil-alkoholno-polivinil-acetatnih kopolimera, PVP, akrilatnih i metakrilatnih kopolimera, metilakrilnokiselinski-metil-metakrilatnog kopolimera, polietilenski-polivinil-alkoholnih kopolimera, polioksietilensko-polioksipropilenskih blok kopolimera, nakalamljenog kopolimera, koji se sastoji od polietilen-glikola, polivinilkaprolaktama i polivinil-acetata, celuloznih polimera, poput hidroksipropil(metil)celuloznog acetata, hidroksipropil(metil)celuloze, hidroksipropilceluloze, metilceluloze, hidroksietil(metil)celuloze, hidroksietilceluloze, hidroksietilceluloznog acetata, te hidroksietil(etil)celuloze, hidroksipropil(metil)celuloznog acetat-sukcinata, hidroksipropil(metil)celuloznog ftalata, karboksimetiletilceluloze, celuloznog acetat-ftalata, celuloznog acetat-sukcinata, hidroksipropil(metil)celuloznog acetat-ftalata, celuloznog acetat-trimelitata, hidroksipropil(metil)celuloznog acetat-trimelitata, te karboksimetilceluloznog acetat-butirata.
4. Čvrsta disperzija u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je disperzijski polimer metilakrilnokiselinski-metil-metakrilatni kopolimer.
5. Čvrsta disperzija u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je disperzijski polimer hidroksipropilmetilcelulozni ftalat.
6. Čvrsta disperzija u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je disperzijski polimer celulozni acetat-ftalat.
7. Čvrsta disperzija u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što se disperzijski polimer bira između vinilpirolidin-vinilacetatnog kopolimera i hidroksipropil(metil)celuloze, ili njihovih smjesa.
8. Čvrsta disperzija u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je disperzijski polimer vinilpirolidin-vinilacetatni kopolimer.
9. Čvrsta disperzija u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je disperzijski polimer hidroksipropil(metil)celuloza.
10. Čvrsta disperzija u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što je N4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloksi)-3-metil-fenil)-N6-(4,4-dimetil-4,5-dihidrooksazol-2-il)kinazolin-4,6-diamin prisutan u količini od otprilike 0,1% do otprilike 50%, težinski, u odnosu na disperzijski polimer.
11. Čvrsta disperzija u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačena time što je najmanje 80% N4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloksi)-3-metilfenil)-N6-(4,4-dimetil-4,5-dihidrooksazol-2-il)kinazolin-4,6-diamina u amorfnom obliku.
12. Čvrsta disperzija u skladu s patentnim zahtjevom 11, naznačena time što je najmanje 95% N4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloksi)-3-metilfenil)-N6-(4,4-dimetil-4,5-dihidrooksazol-2-il)kinazolin-4,6-diamina u amorfnom obliku.
13. Farmaceutski pripravak, naznačen time što sadrži čvrstu disperziju u skladu s bilo kojim od patentnih zahtjeva 1 do 12, kao i jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
14. Farmaceutski pripravak u skladu s patentnim zahtjevom 13, naznačena time što pripravak je tableta.
15. Farmaceutski pripravak u skladu s patentnim zahtjevom 13, naznačen time što sadrži:
(a) otprilike 1 do otprilike 70%, težinski, čvrste disperzije u skladu s bilo kojim od patentnih zahtjeva 1 do 12;
(b) otprilike 0,1 do 20%, težinski, sredstva za raspadanje;
(c) otprilike 0,1 do 25%, težinski, osmogena;
(d) otprilike 0,1 do 10%, težinski, sredstva za kliženje;
(e) otprilike 0,1 do 10%, težinski, maziva; i
(f) otprilike 0,1 do 25%, težinski, veziva.
1. Farmaceutski pripravak u skladu s patentnim zahtjevom 13, naznačen time što sadrži:
(a) N4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloksi)-3-metilfenil)-N6-(4,4-dimetil-4,5-dihidrooksazol-2-il)kinazolin-4,6-diamin; i
(b) natrijev bikarbonat.
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 16, naznačen time što sadrži:
(a) otprilike 1 do otprilike 70%, težinski, čvrste disperzije u skladu s bilo kojim od patentnih zahtjeva 1 do 12; i
(b) otprilike 0,1 do otprilike 30%, težinski, natrijevog bikarbonata.
3. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 13 do 17, naznačen time što čvrsta disperzija je otprilike 25 do otprilike 60%-tna, težinski.
4. Čvrsta disperzija u skladu s bilo kojim od patentnih zahtjeva 1 do 18, naznačena time što je namijenjena upotrebi u liječenju bolesti.
5. Čvrsta disperzija, namijenjena upotrebi u skladu s patentnim zahtjevom 19, naznačena time što je bolest rak.
6. Čvrsta disperzija, namijenjena upotrebi u skladu s patentnim zahtjevom 20, naznačena time što se rak bira između raka dojke, želuca, žučovoda, kolorektalnog raka, pluća, velikih stanica pluća, gušterače, glave i vrata, jajnika, maternice i raka na mozgu.
7. Čvrsta disperzija, namijenjena upotrebi u skladu s patentnim zahtjevima 20 ili 21, naznačena time što je rak pozitivan na ErbB2.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547620P | 2011-10-14 | 2011-10-14 | |
| US201261606207P | 2012-03-02 | 2012-03-02 | |
| PCT/US2012/060044 WO2013056108A2 (en) | 2011-10-14 | 2012-10-12 | Solid dispersion |
| EP12809373.9A EP2765990B1 (en) | 2011-10-14 | 2012-10-12 | Solid dispersion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171578T1 true HRP20171578T1 (hr) | 2017-12-01 |
Family
ID=47471981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171578TT HRP20171578T1 (hr) | 2011-10-14 | 2017-10-17 | Čvrsta disperzija |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US9457093B2 (hr) |
| EP (1) | EP2765990B1 (hr) |
| JP (2) | JP5944514B2 (hr) |
| KR (1) | KR102000312B1 (hr) |
| CN (3) | CN114886853A (hr) |
| AU (3) | AU2012322039C1 (hr) |
| BR (2) | BR122020010643B1 (hr) |
| CA (2) | CA2852058C (hr) |
| CL (1) | CL2014000930A1 (hr) |
| CO (1) | CO6960547A2 (hr) |
| CR (1) | CR20140228A (hr) |
| CY (1) | CY1119837T1 (hr) |
| DK (1) | DK2765990T3 (hr) |
| ES (1) | ES2650608T3 (hr) |
| HR (1) | HRP20171578T1 (hr) |
| HU (1) | HUE035247T2 (hr) |
| IL (1) | IL232103B (hr) |
| LT (1) | LT2765990T (hr) |
| ME (1) | ME02913B (hr) |
| MX (1) | MX353970B (hr) |
| MY (1) | MY169072A (hr) |
| NO (1) | NO2021029I1 (hr) |
| PL (1) | PL2765990T3 (hr) |
| PT (1) | PT2765990T (hr) |
| RS (1) | RS56608B1 (hr) |
| RU (1) | RU2648448C2 (hr) |
| SG (1) | SG11201401459YA (hr) |
| SI (1) | SI2765990T1 (hr) |
| TW (3) | TWI594769B (hr) |
| WO (1) | WO2013056108A2 (hr) |
| ZA (1) | ZA201606123B (hr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013056183A1 (en) | 2011-10-14 | 2013-04-18 | Array Biopharma Inc. | Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them |
| RS56608B1 (sr) * | 2011-10-14 | 2018-02-28 | Array Biopharma Inc | Čvrsta disperzija |
| ES2855142T3 (es) * | 2012-03-23 | 2021-09-23 | Array Biopharma Inc | Compuestos para la utilización en el tratamiento de las metástasis cerebrales en un paciente con cáncer de mama ErbB2+ |
| EP3763702B1 (en) * | 2013-07-19 | 2023-12-13 | Siga Technologies, Inc. | Preparation of amorphous tecovirimat dispersions |
| CN106029065A (zh) * | 2013-12-20 | 2016-10-12 | 法斯瑞斯公司 | 靛玉红固体分散组合物 |
| AU2015214502B2 (en) | 2014-02-05 | 2019-06-06 | Merck Sharp & Dohme Llc | Tablet formulation for CGRP-active compounds |
| EP3307246A1 (en) * | 2015-06-09 | 2018-04-18 | Capsugel Belgium NV | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| CN107126419B (zh) * | 2016-02-26 | 2020-06-19 | 石药集团中诺药业（石家庄）有限公司 | 一种奥贝胆酸片剂及其制备方法 |
| CN107141293B (zh) | 2016-03-01 | 2022-09-23 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| FI3601277T3 (fi) * | 2017-03-30 | 2024-01-09 | Merck Patent Gmbh | Farmaseuttinen formulaatio |
| WO2018201016A1 (en) | 2017-04-28 | 2018-11-01 | Cascadian Therapeutics, Inc. | Treatment of her2 positive cancers |
| TWI780270B (zh) | 2017-11-28 | 2022-10-11 | 靜岡縣公立大學法人 | 固體分散體 |
| CN111818915B (zh) | 2018-01-31 | 2024-05-24 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| CA3094591C (en) * | 2018-04-06 | 2024-03-26 | Capsugel Belgium Nv | Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)] |
| CN109942576B (zh) * | 2019-03-07 | 2020-09-11 | 上海工程技术大学 | Irbinitinib及中间体的制备方法 |
| CN111825604A (zh) * | 2019-04-16 | 2020-10-27 | 宁波药腾医药科技有限公司 | 一种图卡替尼及其中间产物的合成方法 |
| WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| EP4013412A1 (en) | 2019-08-12 | 2022-06-22 | Deciphera Pharmaceuticals, LLC | Ripretinib for treating gastrointestinal stromal tumors |
| US20220378755A1 (en) * | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Pyruvate kinase r (pkr) activating compositions |
| MX2022004699A (es) | 2019-10-21 | 2022-08-08 | Seagen Inc | Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab. |
| EP4058024A1 (en) | 2019-11-15 | 2022-09-21 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
| KR20220123057A (ko) * | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 비정질 키나아제 억제제 제형 및 이의 사용 방법 |
| EP4084779A1 (en) | 2019-12-30 | 2022-11-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| EP4157257A1 (en) | 2020-05-29 | 2023-04-05 | Seagen Inc. | Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy |
| MX2023001233A (es) | 2020-07-29 | 2023-03-02 | Seagen Inc | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab, un taxano y un antagonista del vegfr-2. |
| CN115340541B (zh) * | 2022-07-01 | 2024-01-30 | 上海艾洋化学科技有限公司 | 一种妥卡替尼中间体的制备方法 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| CN115650977A (zh) * | 2022-10-09 | 2023-01-31 | 广东润兴生物科技有限公司 | 一种妥卡替尼的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| EP1350792A1 (en) * | 2000-12-11 | 2003-10-08 | Takeda Chemical Industries, Ltd. | Medicinal compositions improved in solublity in water |
| WO2002048142A1 (fr) * | 2000-12-11 | 2002-06-20 | Takeda Chemical Industries, Ltd. | Compositions medicamenteuses presentant une meilleure absorbabilite |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| ES2399427T3 (es) | 2003-08-14 | 2013-04-01 | Array Biopharma, Inc. | Análogos de quinazolina como inhibidores de los receptores de la tirosina-quinasa |
| GB0321648D0 (en) | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| RU2400227C2 (ru) * | 2004-04-08 | 2010-09-27 | Вайет | Состав, содержащий твердую дисперсию базедоксифен ацетата |
| PT2090575E (pt) | 2005-11-15 | 2011-06-06 | Array Biopharma Inc | Inibidores de erbb |
| EP2140883B1 (en) * | 2007-04-20 | 2012-10-31 | Daido Chemical Corporation | Novel base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion |
| WO2008138755A2 (en) | 2007-05-11 | 2008-11-20 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions for poorly soluble drugs |
| JP2010540460A (ja) | 2007-09-24 | 2010-12-24 | トラガラ ファーマシューティカルズ，インク． | ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療 |
| EP2274609B1 (en) * | 2008-05-05 | 2012-03-28 | Abbott GmbH & Co. KG | Method for evaluating the solubility of a crystalline substance in a polymer |
| EP2158912A1 (en) * | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
| EP2253306A1 (en) * | 2009-05-18 | 2010-11-24 | Royal College of Surgeons in Ireland | Orodispersible dosage forms containing solid drug dispersions |
| RS56608B1 (sr) * | 2011-10-14 | 2018-02-28 | Array Biopharma Inc | Čvrsta disperzija |
| WO2013056183A1 (en) | 2011-10-14 | 2013-04-18 | Array Biopharma Inc. | Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them |
| ES2855142T3 (es) | 2012-03-23 | 2021-09-23 | Array Biopharma Inc | Compuestos para la utilización en el tratamiento de las metástasis cerebrales en un paciente con cáncer de mama ErbB2+ |
-
2012
- 2012-10-12 RS RS20171188A patent/RS56608B1/sr unknown
- 2012-10-12 KR KR1020147012944A patent/KR102000312B1/ko active IP Right Grant
- 2012-10-12 BR BR122020010643-3A patent/BR122020010643B1/pt active IP Right Grant
- 2012-10-12 AU AU2012322039A patent/AU2012322039C1/en active Active
- 2012-10-12 JP JP2014535944A patent/JP5944514B2/ja active Active
- 2012-10-12 ES ES12809373.9T patent/ES2650608T3/es active Active
- 2012-10-12 MY MYPI2014700908A patent/MY169072A/en unknown
- 2012-10-12 RU RU2014119283A patent/RU2648448C2/ru active
- 2012-10-12 PL PL12809373T patent/PL2765990T3/pl unknown
- 2012-10-12 PT PT128093739T patent/PT2765990T/pt unknown
- 2012-10-12 SI SI201231101T patent/SI2765990T1/sl unknown
- 2012-10-12 CA CA2852058A patent/CA2852058C/en active Active
- 2012-10-12 MX MX2014004551A patent/MX353970B/es active IP Right Grant
- 2012-10-12 CN CN202210434174.3A patent/CN114886853A/zh active Pending
- 2012-10-12 US US14/351,840 patent/US9457093B2/en active Active
- 2012-10-12 ME MEP-2017-256A patent/ME02913B/me unknown
- 2012-10-12 HU HUE12809373A patent/HUE035247T2/hu unknown
- 2012-10-12 BR BR112014009092-0A patent/BR112014009092B1/pt active IP Right Grant
- 2012-10-12 CN CN201810490376.3A patent/CN108498465B/zh active Active
- 2012-10-12 CA CA3114454A patent/CA3114454C/en active Active
- 2012-10-12 LT LTEP12809373.9T patent/LT2765990T/lt unknown
- 2012-10-12 EP EP12809373.9A patent/EP2765990B1/en active Active
- 2012-10-12 SG SG11201401459YA patent/SG11201401459YA/en unknown
- 2012-10-12 DK DK12809373.9T patent/DK2765990T3/da active
- 2012-10-12 CN CN201280061909.7A patent/CN103998023B/zh active Active
- 2012-10-12 WO PCT/US2012/060044 patent/WO2013056108A2/en active Application Filing
- 2012-10-15 TW TW101137971A patent/TWI594769B/zh active
- 2012-10-15 TW TW109141025A patent/TWI788733B/zh active
- 2012-10-15 TW TW106116008A patent/TWI722189B/zh active
-
2014
- 2014-04-11 CL CL2014000930A patent/CL2014000930A1/es unknown
- 2014-04-13 IL IL232103A patent/IL232103B/en active IP Right Grant
- 2014-05-14 CR CR20140228A patent/CR20140228A/es unknown
- 2014-05-14 CO CO14103943A patent/CO6960547A2/es unknown
-
2015
- 2015-11-13 JP JP2015223018A patent/JP2016027062A/ja active Pending
-
2016
- 2016-09-05 ZA ZA2016/06123A patent/ZA201606123B/en unknown
- 2016-09-23 US US15/275,163 patent/US20170136022A1/en not_active Abandoned
-
2017
- 2017-07-31 AU AU2017210499A patent/AU2017210499C1/en active Active
- 2017-10-17 HR HRP20171578TT patent/HRP20171578T1/hr unknown
- 2017-10-30 CY CY20171101121T patent/CY1119837T1/el unknown
-
2019
- 2019-01-15 AU AU2019200243A patent/AU2019200243C1/en active Active
- 2019-03-14 US US16/353,951 patent/US20190275043A1/en not_active Abandoned
-
2020
- 2020-12-23 US US17/133,094 patent/US20210220361A1/en not_active Abandoned
-
2021
- 2021-07-09 NO NO2021029C patent/NO2021029I1/no unknown
-
2022
- 2022-08-25 US US17/895,951 patent/US20230097309A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171578T1 (hr) | Čvrsta disperzija | |
| HRP20170620T1 (hr) | Obloženi farmaceutski pripravak koji sadrži regorafenib | |
| JP2017523206A5 (hr) | ||
| JP2017537168A5 (hr) | ||
| JP2005320354A5 (hr) | ||
| RU2017106795A (ru) | Новые составы ингибитора тирозинкиназы брутона | |
| RU2016144479A (ru) | Фармацевтические композиции для лечения заболеваний, опосредопосредованных муковисцидозным трансмембранным регулятором проводимости | |
| JP2013014622A5 (hr) | ||
| HRP20192026T4 (hr) | Formulacija tableta od neratinib maleata | |
| JP2014526508A5 (hr) | ||
| RU2016123828A (ru) | Комбинированная композиция для перорального введения, содержащая эзетимиб и розувастатин | |
| JP2015524472A5 (hr) | ||
| JP2012140433A5 (hr) | ||
| JP2013529637A5 (hr) | ||
| RU2018127873A (ru) | Получение и составление композиции, содержащей ингибитор mek | |
| JP2011241218A5 (hr) | ||
| CA2569683A1 (en) | Oral antimicrobial pharmaceutical compositions | |
| WO2015001489A1 (en) | Pharmaceutical compositions of ticagrelor | |
| EP3041511A2 (en) | Compositions of eltrombopag | |
| JP2020530832A5 (hr) | ||
| CA2787907A1 (en) | Modified release formulation and methods of use | |
| UA112352C2 (uk) | Фармацевтична композиція для профілактики і лікування психічних, поведінкових, когнітивних розладів | |
| WO2012087255A2 (en) | Pharmaceutical formulations | |
| JP2019513801A5 (hr) | ||
| JP2017523149A5 (hr) |